重新审视塔克罗利斯代谢物的性质和药理动力学
Rudy Mevizou1, Hassan Aouad2, François-Ludovic Sauvage2
1Université de Limoges, Inserm, UMR1248, Pharmacology & Transplantation P&T, Limoges, France; Medincell, Jacou, France.
Pharmacological research
|October 2, 2024
概括
塔克罗利斯代谢物,包括M-I,不能解释在广泛代谢器中药物的效率较低. 研究发现,塔克罗利斯代谢物和原始药物之间没有显著的药理学相互作用,排除了这种原因导致患者反应的变化.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 免疫抑制是一种免疫抑制.
背景情况:
- 塔克罗利 (TAC) 是一种重要的免疫抑制剂,但其有效性在患者之间有很大差异,特别是在广泛代谢者中.
- 尽管血液度正常,但毒性较高和疗效较低表明TAC代谢产物或药理动力学 (PD) 相互作用的潜在作用.
- 了解这些相互作用对于优化TAC治疗和患者结果至关重要.
研究的目的:
- 调查塔克罗利斯代谢物和塔克罗利斯之间的潜在的药理学相互作用.
- 描述塔克罗利斯代谢物的结构,包括M-I和M-III,以及它们在患者中的存在.
- 评估这些代谢物对塔克罗利斯免疫抑制活性的影响.
主要方法:
- 使用高分辨率质谱法 (HRMS) 和核磁共振 (NMR) 在体外生产和表征塔克罗利斯代谢物.
- 患者全血和外周血液单核细胞 (PBMC) 中代谢物的量化.
- 在体,体外和活体研究中,探索M-I,塔克罗利斯及其标 (FKBP12,氨酸) 之间的相互作用.
主要成果:
- 在体外和患者血液中发现了塔克罗利斯代谢物 (M-I,M-III) 的开环异构体,但没有通过NMR检测到.
- 在表达CYP3A5.5的移植患者中观察到较高的MI/TAC比率.
- 在和体外实验表明,包括M-I在内的代谢物结合FKBP12,但与塔克罗利相比,表现出较弱的氨酸 (CN) 和下游信号 (IL2,NFAT) 抑制,没有观察到竞争性PD相互作用.
结论:
- 塔克罗利斯代谢物,包括M-I及其异构体,似乎不会与塔克罗利斯进行药理学相互作用,从而降低其疗效.
- 在广泛代谢剂中观察到的塔克罗利斯疗效和毒性的变化不太可能是由于PD与其代谢物的相互作用.
- 可能需要进一步的研究来探索其他因素,有助于塔克罗利斯反应的个体间变化.
相关概念视频
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
106
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
106
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
102
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
102
Drug Concentration Versus Time Correlation
660
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
660
Nonlinear Pharmacokinetics: Causes of Nonlinearity
144
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
144
Factors Affecting Drug Biotransformation: Biological
124
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
124
Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K


